Adopting Adaptimmune
Why investors preferred Adaptimmune's TCR platform to other T cell therapy cos
Adaptimmune Ltd. attracted its first institutional investors with the maturity of its engineered T cell receptor platform, which could access more and different targets than chimeric antigen receptor therapies.
New investor New Enterprise Associates led last week's $104 million round, joined by new investors OrbiMed Advisors, Wellington Management, Fidelity Biosciences, Foresite
